25,179 Shares in Bruker Co. (BRKR) Acquired by Magnetar Financial LLC

Magnetar Financial LLC purchased a new position in shares of Bruker Co. (NASDAQ:BRKR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,179 shares of the medical research company’s stock, valued at approximately $749,000.

Several other institutional investors also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC grew its holdings in Bruker by 496.1% during the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock worth $110,000 after acquiring an additional 3,185 shares during the period. SG Americas Securities LLC acquired a new position in Bruker during the second quarter worth $111,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Bruker by 11.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 467 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Bruker by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after acquiring an additional 331 shares during the period. Finally, Advisory Services Network LLC grew its holdings in Bruker by 6.3% during the second quarter. Advisory Services Network LLC now owns 6,847 shares of the medical research company’s stock worth $197,000 after acquiring an additional 406 shares during the period. Institutional investors and hedge funds own 65.63% of the company’s stock.

Shares of Bruker Co. (NASDAQ BRKR) opened at $34.27 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. The firm has a market capitalization of $5,416.69, a price-to-earnings ratio of 29.76, a price-to-earnings-growth ratio of 2.94 and a beta of 1.12. Bruker Co. has a twelve month low of $21.03 and a twelve month high of $36.53.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The company had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. Bruker had a return on equity of 25.83% and a net margin of 8.85%. Bruker’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.32 earnings per share. equities research analysts forecast that Bruker Co. will post 1.19 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 22nd. Stockholders of record on Monday, December 4th will be given a $0.04 dividend. The ex-dividend date of this dividend is Friday, December 1st. This represents a $0.16 annualized dividend and a dividend yield of 0.47%. Bruker’s dividend payout ratio is currently 17.02%.

In other news, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total value of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares in the company, valued at $1,813,904.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 35.20% of the stock is owned by corporate insiders.

A number of brokerages recently weighed in on BRKR. BidaskClub raised Bruker from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Goldman Sachs Group reaffirmed a “sell” rating and set a $24.00 price objective on shares of Bruker in a report on Tuesday, September 26th. J P Morgan Chase & Co raised Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price objective on the stock in a report on Friday, November 3rd. Cowen reissued a “hold” rating and issued a $29.00 target price on shares of Bruker in a report on Friday, November 3rd. Finally, Bank of America raised Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price on the stock in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $29.64.

ILLEGAL ACTIVITY WARNING: This story was originally published by Week Herald and is owned by of Week Herald. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://weekherald.com/2017/12/12/25179-shares-in-bruker-co-brkr-acquired-by-magnetar-financial-llc.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply